Condition 1: Multiple sclerosis. Condition 2: Overactive Bladder Disorder. Multiple sclerosis Other disorders of bladder
Conditions
Interventions
Intervention 1: First Intervention group: Drug treatment The oral tablet of Sulifenacin succinate 5 mg under the brand name Vsol (Abidi Company) is used. It was developed in 2004 and is one of the ant
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: No infection in the Urinary tract Have a minimum score of 3 in the Actionable questionnaire to confirm Neurogenic overactive Bladder Urinary incontinence that may or may not be accompanied by urgent Urinary incontinence At least 1 month has passed since the onset of symptoms of overactiveBladder disorder At least one month has passed since the last MS attack EDSS scale (severity of degree of disability) 1 to 5.5
Exclusion criteria
Exclusion criteria: Pregnant Women and those who want to get Pregnant within the next year Allergy to the Drug Sulifenacin such as Angioedema Heart problems (such as Heart failure) Have a history of surgery to treat Urinary incontinence or other Urinary tract surgeries Having stress Urinary incontinence Having Diabetes and Neurological diseases such as Parkinson's History of Anticholinergic Drug therapy for the treatment of overactive Bladder during the last month History of Electrotherapy treatment in the lower limbs and lower back and history of Pelvic floor Muscle Physiotherapy during a recent month Having a Heart Pacemaker and a Prosthesis in the leg Having a lesion at the site of Electrical stimulation of the Posterior Tibial Nerve
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of Urinary Symptoms. Timepoint: Evaluation of urinary symptoms at the beginning of the study (before the intervention) and 4, 8 and 12 weeks after the intervention. Method of measurement: International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB).;Urinary Incontinence. Timepoint: Evaluation of urinary incontinence at the beginning of the study (before the intervention) and 4, 8 and 12 weeks after the intervention. Method of measurement: International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form(ICIQ-UI SF). | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality Of Life. Timepoint: Evaluation of Quality of life at the beginning of the study (before the intervention) and 4, 8 and 12 weeks after the intervention. Method of measurement: Multiple Sclerosis Quality of Life Questionnaire (MSQOL-54). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Jafari
Ahvaz University of Medical Sciences
Outcome results
None listed